role of ivig in the management of neonatal isoimmune hemolytic jaundice

© 2003 By Default!

A Free sample background from www.awesomebackgrounds.com

Slide 1

‘ROLE OF IVIG IN THE MANAGEMENT OF NEONATAL ISOIMMUNE HEMOLYTIC JAUNDICE’

MEETA SACHDEV G.MALINI, P.N.AGRAWAL, S.M.DEWANGAN

DEPTT. OF PEDIATRICS JLN HOSPITAL & RESEARCH CENTRE BHILAI

© 2003 By Default!


Slide 2

INTRODUCTION

Neonatal jaundice: Common in 1st wk of life

60% of term & 80% of preterm infants.

Clinical jaundice: Bilirubin >7 mg/dl.

Mostly physiologic

© 2003 By Default!


Slide 3

NONPHYSIOLOGIC JAUNDICE IN WELL INFANT

Hemolytic disease of newborn (ABO/Rh)

Incidence of ABO incompatibility : 25%

significant jaundice : 2.5%

Incidence of Rh incompatibility : 4.8%

significant jaundice : 0.17 – 0.31%

Gupte et al. Natl Med J India 1994; 7: 65-66

© 2003 By Default!


Slide 4

WHY WORRY

Clinically indistinguishable

Bilirubin rises to toxic

levels

Acute bilirubin

encephalopathy

Left with sequelae-

KERNICTERUS

Athetosis, sensorineural

deafness, intellectual

deficits

© 2003 By Default!


Slide 5

CONVENTIONAL MANAGEMENT

Intensive phototherapy (excretion by alternative pathways)

Maintain hydration & increase feeds

(decreases enterohepatic circulation)

Exchange transfusion (mechanical removal)

© 2003 By Default!


Slide 6

EXCHANGE TRANSFUSION Prerequisites

Invasive procedure

Trained personnel

Well-equipped setup

Sepsis screen & blood

culture

Parentral fluids &

prophylactic antibiotics

Near- fatal

complications(5%) &

mortality (1%)

© 2003 By Default!


Slide 7

COMPLICATIONS OF EXCHANGE TRANSFUSION

RISK OF EXPOSURE TO BLOOD COMPLICATIONS OF UVC Hypocalcaemia , hypomagnesaemia, hyperkalemia Hypoglycemia, acid-base disturbances Cardiovascular, apnea, seizures Bleeding, hemolysis Infection Misc- hypo/hyperthermia, NEC. Etc.

© 2003 By Default!


Slide 8

IVIG IN HDN -AAP GUIDELINES

Indication: Hemolytic disease of newborn with

significant

hyperbilirubinemia

Dose: 0.5-1gm/kg

Mode of administration: Infusion given over 2-4

hrs.

Monitoring: For adverse reactions

(Pediatrics 2004;114:297-316)

© 2003 By Default!


Slide 9

YY

Y

YYY

YY Y

Y

Y

Y Y

Y

Y

Y

Y

Y Y

YYY Y Y

Y

Y

Y Y

Y

Fetal RBC

Maternal Antibodies

Y

RE cell

Lysis of RBC

IVIG

BlockadeMECHANISM OF IVIG

ImmunoglobulinFc

© 2003 By Default!


Slide 10

WHY THIS STUDY

After publication of AAP guidelines,

IVIG is being used more frequently in HDN.

Is IVIG useful only to bring down the bilirubin

level ?

Are there any more advantages?

What is our experience?

© 2003 By Default!


Slide 11

AIMS & OBJECTIVES

To evaluate the efficacy of IVIG in HDN

To compare the stay, cost of treatment

& complications between IVIG & Exchange group

Which is safer?

© 2003 By Default!


Slide 12

MATERIAL & METHODS

TYPE OF STUDY : OBSERVATIONAL

TIME FRAME : JAN 2010 – DEC 2011

NO. OF SUBJECTS : 16(16) INCLUSION CRITERIA : Healthy neonates (>35wks),

HDN & significant

hyperbilirubinemia EXCLUSION CRITERIA : Sick neonates & gestation

<35 wks.

© 2003 By Default!


Slide 13

MATERIAL & METHODS

Blood grouping of infants whose mother’s blood

group is O/Rh negative

Close monitoring for clinical jaundice

Measurement of serum bilirubin levels

© 2003 By Default!


Slide 14

MATERIAL & METHODS

INTENSIVE PHOTOTHERAPY & Maintain hydration

INTRAVENOUS IMMUNOGLOBULIN INFUSION : Rising bilirubin level despite intensive phototherapy OR bilirubin levels were within 2-3 mg % of exchange

levels

EXCHANGE TRANSFUSION : Bilrubin level >5mg% of exchange threshold

© 2003 By Default!


Slide 15

AAP GUIDELINES FOR PHOTOTHERAPY(Pediatrics 2004;114:297-316)

© 2003 By Default!


Slide 16

AAP GUIDELINES FOR EXCHANGE TRANSFUSION

(Pediatrics 2004;114:297-316)

© 2003 By Default!


Slide 17

OBSERVATIONS

© 2003 By Default!


Slide 18

SEX DISTRIBUTION

Female : male = 1.28: 1

© 2003 By Default!


Slide 19

GESTATION

© 2003 By Default!


Slide 20

WEIGHT

© 2003 By Default!


Slide 21

INCOMPATIBILITY

© 2003 By Default!


Slide 22

BIRTH ORDER

© 2003 By Default!


Slide 24

SERUM BILIRUBIN LEVELS

Peak bilirubinMean value

(Age in days)

After 24 hrs

After 48 hrs

After 72 hrs

IVIG19.53

(2.5 Days)

16.31 13.16 9.95

p < 0.005Significant

p< 0.001Highly

significant

p < 0.001Highly

significant

Exchange transfusion

25.09 (3.75 Days)

18.82 13.23 9.68

p < 0.001Highly

significant

p < 0.001Highly

significant

p < 0.001Highly

significant

© 2003 By Default!


Slide 26

PARENTRAL FLUIDS & ANTIBIOTICS

ANCILLARY TREATMENT IVIG EXCHANGE

TRANSFUSION

IV FLUIDS 3 (19%) 16 (100%)

ANTIBIOTICS

First line 3 (19%) 0

Broad spectrum 2 (13%) 9 (56%)

Extended spectrum 0 7 (44%)

DURATION OF ANTIBIOTICS

2-5 D 5 (31%) 4 (25%)

6-10 D 0 4 (25%)

11-14 D 0 8 (50%)

© 2003 By Default!


Slide 27

MEAN VALUES IVIG group Blood exchange group

p value(Unpaired T

test) Significance

DURATION OF PHOTOTHERAPY 5.5 Days 4.5 Days p > 0.05

Not significant

HOSPITAL STAY 7.2 Days 9.6 Days p < 0.05Significant

COST ( Rs) 13,500 22,200 p < 0.005Highly significant

DURATION & COST OF T/T

© 2003 By Default!


Slide 28

ADVERSE EFFECTS IN EXCHANGE TRANSFUSION

Hypoc

alce

mia

Throm

bocy

tope

nia

Prove

n se

psis

Seizu

res

Anem

ia

Hyper

sens

itivity

0%

20%

40%

60%

80%

100%

44%

25%19% 19%

13%

0%

%

of

pa

tien

ts

© 2003 By Default!


Slide 29

CONCLUSION

Predicting the risk of severe jaundice, close

monitoring & follow-up is crucial in ABO & Rh

incompatibility

Early intervention with intensive phototherapy &

IVIG is helpful in averting exchange transfusion, its

associated risks & complications significantly

Duration of stay & cost of treatment is significantly

reduced

© 2003 By Default!


Slide 30

REFERENCES Alcock GS, Liley H. Immunoglobulin infusion for isoimmune

hemolytic jaundice in neonates (review). Cochrane Database Syst Rev 2001;(4)

Vinayaka G et al. role of intravenous immunoglobulin in the management of hemolytic disease of newborn. Pediatrics Today Vol XII No. 6,2009

Alpay F et al. High dose intravenous immunoglobulin therapy in neonatal immune hemolytic jaundice. Acta Pediatr 1999;88:216-119

Patra K. Adverse effects associated with neonatal exchange transfusion in the 1990s. J Pediatr 2004;144:626-31

Mukhopadhyay K et al.Intravenous immunoglobuin in rhesus hemolytic disease. Indian J Pediatr 2003;70:697-9

Miqdad AM et al. IVIG therapy for significant hyperbilirubinemia in ABO hemolytic disease of newborn. J Matern Fetal Neonatal Med 2004;16:163-6

© 2003 By Default!


Slide 32

TIMING OF FOLLOW-UP (Pediatrics 2004;114:297-316)

Infant discharged

Before age 24 h

Between 24 & 48 h

Between 48 & 72 h

follow-up by

72 h

96 h

120 h

role of ivig in the management of neonatal isoimmune hemolytic jaundice

Education

weighta free sample

significant jaundice

days p

ivig exchange group

role of ivig

efficacy of ivig

ivig useful

clinical jaundice